ESMO

Pembrolizumab in HPV-Positive Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Cetuximab, Fluorouracil, and Cisplatin, with/without Docetaxel, in Recurrent or Metastatic Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Dose-Ranging Phase 2 Results of Nivolumab Therapy in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Pembrolizumab in the Treatment of Patients with Advanced Urothelial Tract Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Interim Analysis of BATON-CRC: Tivozanib plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent

Updated STRIDE and STAND Trial Results: Optimal Sipuleucel-T Use in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent

Page 5 of 8

1
2
3
4
5
6
7
8

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

VBCC Print Edition

VBCC Weekly e‑Newsletter

I have reviewed and consent to the terms of VBCC's Privacy Policy, and VBCC has my permission to retain my information in its database, and to forward pertinent communications to me.